Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ceftobiprole meets Phase III CAP endpoint

Basilea (SWX:BSLN) said ceftobiprole ( BAL5788) met the primary endpoint of non-inferiority vs.

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE